MCO
NYSE · Financial Services
Moody'S Corp
$467.22
-1.37 (-0.29%)
MCO News16 articles
S&P Global shares slide 5% as ratings and indices drive 77% of growth post spin-off
S&P Global shares dropped 5% as its ratings and indices businesses drove 77% of pro forma revenue growth, raising questions about diversification.
MSCI Stock Drops 12% on Rising Costs Despite Record Index Fees
MSCI shares slid 12.4% as record index fees were overshadowed by higher expense forecasts, with operating expense midpoint rising $45 million while free cash flow guidance increased only $15 million.
Zurich Adds to Beazley Stake, Merger Spread Narrows
Zurich Insurance bought another 494,252 Beazley shares, raising its stake to 6.31%. The move tightens the merger spread to 1.79%, signaling confidence in the £1,310p per share cash offer.
Theo Invests $20M in Fidelity International Tokenized Fund, FILQ
Theo invested $20 million in Fidelity International's FILQ tokenized fund via Sygnum, the first crypto-native platform allocation. FILQ's onchain assets total $55.1 million.
Greg Abel Consolidates Control of Berkshire's Portfolio, Shifts Focus to Japan
Greg Abel has tightened his grip on Berkshire Hathaway's $300 billion stock portfolio, increasing exposure to Japan while trimming U.S. holdings like Apple and Amazon.
Mastercard Advances Stablecoin Settlement with SoFi, Shares Gain After Hours
Mastercard shares gained 0.6% in extended trading following news of a partnership with SoFi Technologies to integrate stablecoin settlement into its global payments network. Investors await further strategic updates at an upcoming investor conference.
S&P Global Rallies Into Holiday Weekend Amid AI Uncertainty; Key Data Ahead
S&P Global shares jumped 3.3% Friday, closing at $409.54 on volume more than double average, recovering from recent AI-related pressures. Key economic data and Fed minutes loom next week.
S&P Global Shares Rally Amid Analyst Target Cuts and Insider Buying
S&P Global shares advanced 3.1% to $409.54 on elevated volume, though remain 29% below their 52-week high. Analysts trimmed price targets but maintained bullish ratings.
S&P Global Shares Rebound After Profit Guidance Sparks Selloff
S&P Global shares gained 1.7% on Thursday, rebounding after a two-day slide. The stock had fallen following the company's 2026 adjusted EPS guidance, which came in below its medium-term targets.
Moody's Shares Steady After Sector Rout, Focus Turns to Earnings
Moody's shares held near $418 in premarket trading following a sharp sector selloff. Investors await next week's earnings for insights on debt issuance and analytics demand.
S&P Global Shares Drop 7% on Disappointing 2026 Profit Outlook
S&P Global stock fell sharply after its 2026 adjusted EPS forecast of $19.40-$19.65 missed the $19.94 consensus, with investors eyeing billed issuance data and the timing of its Mobility spin-off.
S&P Global Tumbles on Subpar 2026 Forecast, Drags Down Financial Data Peers
S&P Global shares fell sharply after issuing a 2026 profit outlook below analyst expectations, sparking a sell-off in related financial information stocks.
S&P Global Shares Hold Steady Ahead of Q4 Earnings, Focus on 2026 Outlook
S&P Global shares edged higher to $439.92 in Monday trading as investors await the company's fourth-quarter results and 2026 guidance. The stock remains near its 52-week low.
Moody's: South Africa's Debt Stabilizing, Iran Conflict Poses Growth Risk
Moody's says South Africa's debt has peaked at 86.8% of GDP and is set to decline, but warns the Iran conflict could reduce growth by up to 0.5 percentage points in 2026-27.
Dubai Property Braces for Supply Surge as Moody's Warns of Price Slowdown
Dubai's real estate market faces a significant influx of new residential supply between 2026 and 2028, which analysts warn could temper price growth. Strong foreign investment, particularly from India, continues to underpin transaction activity.
AbbVie Gains on Moody's Credit Upgrade, Focus Shifts to Immunology Portfolio
AbbVie shares rose 2% to $223.43 after Moody's upgraded its credit rating to A2 with a stable outlook. Investors now watch demand and pricing for Skyrizi and Rinvoq amid Humira competition.